Pharmaceuticals, Biotechnology & Life Sciences

Insider buying spree at Mesoblast shows CFO and execs expect a rise—backed by new CAR‑T therapy data and strong social buzz, but still a volatile, loss‑making biotech.

Insider buys at Personalis show CEO Hall Christopher M’s confidence in its 50%+ rally, yet investors should watch FDA milestones before betting big.

Insider sales at Abeona signal tax‑planning, not panic—yet investors should watch for pipeline wins and liquidity shifts.

Insider buys at Neurocrine reveal confidence in its neuro‑psychiatric pipeline and upside potential—see how the CEO’s 10b5‑1 trades signal long‑term optimism.

Insight: Borgeson Blake’s July 7 insider sale of 40,000 Recursion shares—priced at $3.96—signals cautious liquidity amid rising buzz, urging investors to watch short‑term volatility and the company’s AI‑driven drug pipeline for long‑term confidence.

Insider trading at Immunome shows steady, rule‑based moves—buy low, sell high—hinting at confidence while highlighting a long‑term upside amid current valuation gaps.

Insight into Robert Hershberg’s July 7 insider trades at AtaiBeckley reveals a neutral, rule‑based strategy and its impact on investor sentiment and the company’s volatile biotech stock.

Insider buying fuels Quantum Cyber’s pivot to healthcare cybersecurity—executives’ confidence signals a possible upside reversal.

IDEAYA insider Ruiz Briseno’s July 7, 2026 buy‑sell‑exercise move shows deep confidence in the company’s oncology pipeline and hints at future upside for shareholders.

Metzger’s dual buy‑sell move shows insider confidence in Syndax’s pipeline—locking in gains while keeping a large stake, a signal that may boost investor optimism.